Trials / Recruiting
RecruitingNCT04766177
Role of Bumetanide in Treatment of Autism
Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Sherief Abd-Elsalam · Academic / Other
- Sex
- All
- Age
- 3 Years – 12 Years
- Healthy volunteers
- Not accepted
Summary
Role of bumetanide in Autism
Detailed description
Role of Bumetanide in Treatment of Autism spectrum disorder in children
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bumetanide | bumetanide 0.5 mg twice daily |
| DRUG | Placebo | placebo tablets twice daily |
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2030-12-01
- Completion
- 2030-12-01
- First posted
- 2021-02-23
- Last updated
- 2021-02-23
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04766177. Inclusion in this directory is not an endorsement.